PERIPHERAL T-CELL LYMPHOMA
Clinical trials for PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo tested in fight against Tough-to-Treat blood cancer
Disease control TerminatedThis early-stage trial tested the safety and best dose of a two-drug combination (parsaclisib and chidamide) for people with a fast-growing type of blood cancer called peripheral T-cell lymphoma that has come back or stopped responding to standard treatments. The main goals were …
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Apr 04, 2026 05:06 UTC
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control TerminatedThis study tested whether adding a drug called selinexor to standard chemotherapy or an immunotherapy drug (tislelizumab) could help control advanced T-cell and NK-cell lymphomas that had returned or stopped responding to prior treatments. It involved adults whose cancer had come…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Antengene Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC